Employees at Achilles Therapeutics are bracing themselves for job losses after the UK biotech announced that it is dropping its R&D in tumour-infiltrating lymphocyte (TIL) therapies for
The UK's biotechnology sector is going through a purple patch, attracting almost £1.6 billion ($2.2 billion) in financing in the three months to end-May – which is a record for the industry
UK biotech Achilles Therapeutics has completed its initial public offering (IPO) in the US, raising $175.5 million that will be used to take its personalised T cell therapy for lung and ski